Universität Bielefeld

© Universität Bielefeld

Call for Applications has been extended for ESR Position 05!

The Marie-Sklodowska-Curie European Training Network Magicbullet :: Reloaded will develop and employ approaches for selective, targeted delivery of a panel of anticancer drugs for directed tumor therapy. The activities of the consortium will be devoted to four different project areas:

  • Small molecule-drug conjugates (SMDCs) and peptide-drug conjugates (PDCs)
  • Multivalency and crosstalk with the immune system
  • Pharmacokinetics: Transport, drug release, and metabolism
  • Biological evaluation of the conjugates

EU This project has received funding from the European Union′s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 861316.

The Marie-Sklodowska-Curie Innovative Training Network (ITN) Magicbullet::Reloaded offers 15 three-years fixed-term PhD positions

The ETN Magicbullet::Reloaded will provide young researchers a unique portfolio of multidisciplinary competences, cutting-edge proficiencies and transferable soft skills to push the boundaries of frontier research within the EU. The ESRs will be involved in all stages of drug development, ranging from Synthetic Chemistry over Medicinal Chemistry to Tumor Biology and Assay Development in a highly cross-linked, inter-sectoral research network between academia and industry. This network warrants cutting-edge interdisciplinary education, supplemented by a well-balanced and tailor-made training in transferable soft skills, directly focussed on the demands and needs of each individual researcher.

The ETN will recruit 15 highly talented early stage researchers (ESR) with background in the relevant scientific areas. This high complementarity is required for the different scientific tasks in the development pipeline. Vice versa, the ESRs will be exposed to a challenging research environment leading to a broad range of scientific competences to be acquired.

Eligibility criteria

All applicants must be Early-Stage Researchers (ESRs) who are in the first four years (full-time equivalent research experience) of their research careers, starting from the date when the M.Sc. degree (or similar) was awarded. They must not hold a doctoral degree.

Persons from any nationality may apply, but transnational mobility is indispensable: You may only apply for a position in a particular project if you did not reside or carry out your main activity (such as work or study) in this country for more than 12 months within the last 3 years. This excludes short stays such as holidays or compulsory national service.
Employment conditions
The selected candidates will receive a 36-month, full-time employment contract as per Marie Sklodowska-Curie Actions (MSCA) regulations for early stage researchers. Marie Curie ITNs provide a highly competitive salary to the ESR, including a generous monthly living and mobility allowance and (if eligible) a monthly family allowance. The exact salary will be confirmed upon appointment. In particular, it consists of:
  • living allowance: 3.270 EUR/month (39.240 EUR/year), multiplied by the country correction coefficient of the country where the researcher is recruited:
    • Finland: 120.8%
    • Germany: 97.0%
    • Hungary: 77.4%
    • Italy: 104.4%
    • Switzerland: 121.2%
    • UK: 139.8%
  • mobility allowance: 600 EUR/month
  • family allowance, if applicable - depending on the family situation at the time when the contract is being concluded: 500 EUR/month
It must be noted that the living allowance is a gross EU contribution to the salary costs of the researcher. Consequently, the net salary results from deducting all compulsory social security contributions (employee and employer) as well as direct taxes (e.g. income tax) from the gross amounts. The rate indicated here is for researchers devoting themselves to their project on a full-time basis.

The mobility and family allowance is a fixed amount, regardless of the country of recruitment, and may be taxable depending on the country in which the researcher is recruited.

In the frame of a secondment, each ESR will spend seven months at the premises of another ETN consortium member. The transnational mobility rule does not apply for the secondments.

Further information regarding eligibility and salary can be found on the MSCA website.

Application Procedure

We are looking forward to hearing from you! Please download the application form via this link .

In order for your application to be considered please send the filled application form together with the following documents in English as single PDF-file to magicbullet@uni-bielefeld.de:
  • Completed application form
  • Curriculum vitae including relevant skills, experience and publication list
  • Motivation letter (1 page)
  • University transcripts and certificates: Bachelor and Master degrees. For EU Countries, the Diploma Supplement is recommended.
  • University entrance diploma

In addition, two reference letters from e.g. former supervisors are required that have to be sent separately and confidentially by the referees to magicbullet@uni-bielefeld.de.

Please notice that the individual requirements for each ESR project are mentioned in the list below.

Incomplete applications and all other ways or forms of application will not be considered! All applications will be deleted at the end of the selection procedure.

Application Deadline: 27.07.2020

Open ESR Positions

ESR 05 - Fraunhofer ITEM, Germany

Identification of patient-specific targets to selectively treat tumor-associated macrophages (TAMs) in organotypic tumor slices of NSCLC and glioblastoma


Glioblastoma multiforme (GBM) and Non-Small Cell Lung Cancer (NSCLC) have severe implications on quality of life and survival of diseased patients. TAMs were identified as prognostic marker in these cancer entities, repolarisation of TAM macrophages using RNA therapeutics was identified as a new potential therapy. Using viable human tumor tissue slices or tumor organoids, TAM related targets will be identified by phage display library and used for design of a drug delivery system to address repolarisation of TAMs. Efficacy of the treatments will be assessment in precision cut tumor tissues and spheroids.

Further information can be found here
Dr. Katherina Sewald

Dr. Katherina Sewald

Fraunhofer ITEM, Germany

Preclinical Pharmacology and in vitro Toxicology

Planned Secondment Host for 7 months

Dr. Giuseppe Roscilli

Dr. Giuseppe Roscilli

Takis Biotech SRL, Italy

Drug Evaluation and Monoclonal Antibodies